New York-based Metsera, a biopharma developing medicines for obesity and metabolic diseases, has closed a $215 million Series ...

Digital therapeutics company GAIA has announced the signing of a licensing agreement for attexis with fellow German firm ...

Syncona has launched Slingshot Therapeutics with an initial $15 million investment through its Syncona Accelerator initiative ...

Adaptimmune’s Phase II trial of lete-cel showed a 42% response rate in synovial sarcoma and MRCLS, with strong median ...

Danish allergy immunotherapy specialist ALK Abello today posted financial results for the third quarter of 2024, which ...

Pharma major Bristol Myers Squibb (NYSE: BMY) and US biotech Cabaletta Bio are set to present promising Phase I data on ...

Sino-American firm Insilico Medicine has shown the potential not just of its pipeline and lead candidate by presenting ...

Apollo Therapeutics and Sunshine Lake Pharma have signed a license deal for APL-18881, a bi-specific fusion protein targeting ...